Q-omics provides the consensus-scored MIR2278 profile across patient tissues and cancer cell-line models. MIR2278 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MIR2278 is differentially expressed in 4, with the highest sampling consensus in ESCA. Additionally, MIR2278 RNA expression shows 10,943 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, ESCA, and LSCC as cancer lineages where MIR2278 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR2278 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR2278 survival associations across molecular data types. MIR2278 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR2278 RNA expression–survival associations across cancer types. High MIR2278 expression shows unfavorable associations in TGCT, KIRC and SKCM, but favorable associations in HNSC, BRCA and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify HNSC as the clearest survival context for MIR2278 RNA expression.
This table summarizes MIR2278 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in ESCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR2278. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR2278 shows lower tumor expression in KICH and higher tumor expression in ESCA, STAD and UCEC. The ESCA box plot shows higher MIR2278 RNA expression in tumor versus normal tissue (log2 FC = +1.025, t-test p < 0.001).
This table shows molecular features associated with MIR2278 in patient tissues and cancer cell lines. In patient samples, MIR2278 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
